Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Usman Baber

Showing results (41-50 of 391) with videos related to

Pageof 40
Sort By:
Journal of the American College of Cardiology|November 2, 2019
Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty?Roxana Mehran, Davide Cao, Usman Baber
JACC. Cardiooncology|August 16, 2021
Ticagrelor in Patients With Cancer: 2 Birds With 1 StoneRoxana Mehran, Davide Cao, Usman Baber
Interventional Cardiology Clinics|June 6, 2017
Future Perspectives on Percutaneous Coronary Interventions in WomenJennifer Conroy, Usman Baber, Roxana Mehran
Journal of the American College of Cardiology|March 21, 2015
DAPT duration after DES: what is the "mandatory" duration?Roxana Mehran, Gennaro Giustino, Usman Baber
Revista Espanola De Cardiologia (English Ed.)|November 4, 2018
Limitations of Current Risk Scoring in Real World Populations: The Importance of External ValidationSabato Sorrentino, Usman Baber, Roxana Mehran
Current Opinion in Cardiology|May 21, 2014
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?Georgios Christodoulidis, Usman Baber, Roxana Mehran
Journal of the American Heart Association|November 21, 2016
Anemia and Acute Coronary Syndrome: Time for Intervention StudiesSerdar Farhan, Usman Baber, Roxana Mehran
European Heart Journal|February 22, 2021
Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary interventionDavide Cao, Usman Baber, Roxana Mehran
The New England Journal of Medicine|March 12, 2020
Ticagrelor with or without Aspirin after PCI. ReplyUsman Baber, George Dangas, Roxana Mehran
Nature Reviews. Cardiology|November 5, 2014
Balancing ischaemia and bleeding risks with novel oral anticoagulantsUsman Baber, Ioannis Mastoris, Roxana Mehran
Pageof 40

Showing results (41-50 of 391) with videos related to

Sort By:
Pageof 40
Journal of the American College of Cardiology|November 2, 2019
Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty?Roxana Mehran, Davide Cao, Usman Baber
JACC. Cardiooncology|August 16, 2021
Ticagrelor in Patients With Cancer: 2 Birds With 1 StoneRoxana Mehran, Davide Cao, Usman Baber
Interventional Cardiology Clinics|June 6, 2017
Future Perspectives on Percutaneous Coronary Interventions in WomenJennifer Conroy, Usman Baber, Roxana Mehran
Journal of the American College of Cardiology|March 21, 2015
DAPT duration after DES: what is the "mandatory" duration?Roxana Mehran, Gennaro Giustino, Usman Baber
Revista Espanola De Cardiologia (English Ed.)|November 4, 2018
Limitations of Current Risk Scoring in Real World Populations: The Importance of External ValidationSabato Sorrentino, Usman Baber, Roxana Mehran
Current Opinion in Cardiology|May 21, 2014
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?Georgios Christodoulidis, Usman Baber, Roxana Mehran
Journal of the American Heart Association|November 21, 2016
Anemia and Acute Coronary Syndrome: Time for Intervention StudiesSerdar Farhan, Usman Baber, Roxana Mehran
European Heart Journal|February 22, 2021
Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary interventionDavide Cao, Usman Baber, Roxana Mehran
The New England Journal of Medicine|March 12, 2020
Ticagrelor with or without Aspirin after PCI. ReplyUsman Baber, George Dangas, Roxana Mehran
Nature Reviews. Cardiology|November 5, 2014
Balancing ischaemia and bleeding risks with novel oral anticoagulantsUsman Baber, Ioannis Mastoris, Roxana Mehran
Pageof 40